KRAS and familial pancreatic carcinoma: Pancreatic cancer: a study integrating bioinformatics resources demonstrated that KRAS-driven gene signature plays a crucial role in disease progression and prognosis, and that Fedratinib might be able to reverse the KRAS-driven gene signature, therefore establishing promising therapeutic benefits in this subgroup of patients [48].